1. Autoantibodies against 'rods and rings'-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a 'real life' cohort.
- Author
-
Dammermann, Werner, Polywka, Susanne, Dettmann, Inga, Mindorf, Swantje, Komorowski, Lars, Wehmeyer, Malte, Schulze zur Wiesch, Julian, Stöcker, Winfried, and Lüth, Stefan
- Subjects
- *
HEPATITIS C , *ANTIVIRAL agents , *AUTOANTIBODIES , *DEHYDROGENASES , *VIROLOGY , *IMMUNOLOGY - Abstract
Autoantibodies against inosine-5′-monophosphate-dehydrogenase-2 (IMPDH2; 'rods and rings' pattern) develop in chronic hepatitis C (CHC) patients under treatment with peg-interferon (IFN) and ribavirin (RBV), an inhibitor of IMPDH2. We investigated the influence of the alternative therapy with direct-acting antivirals (DAA)/ribavirin on anti-IMPDH2 autoantibody generation and the use of anti-IMPDH2 development as a marker for therapy outcome (sustained virologic response, SVR). We analyzed a 'real life' cohort of 104 unselected CHC genotype 1 (GT1) patients treated with IFN/first-generation DAA/RBV prospectively compared to a historic cohort of 59 IFN/RBV-treated CHC GT1 patients. First-generation DAA were boceprevir (BOC) or telaprevir (TPR). Serum autoantibodies were tested by indirect immunofluorescence (IFA) using recombinant IMPDH2 expressing HEK293 cells and native HEp2-cells as substrates. 64/163 (39%) CHC patients turned anti-IMPDH2 positive during therapy, but only 43/163 (26%) showed also 'rods and rings' structures. 99/163 (61%) were tested as anti-IMPDH2 negative. 53/104 (51%) CHC patients undergoing IFN/DAA/RBV therapy were anti-IMPDH2 positive and 38/104 (37%) were in parallel anti-'rods and rings' positive. HCV clearance/SVR rate after IFN/DAA/RBV therapy and anti-IMPDH2 status were not significantly dependent. CHC GT1 patients treated with IFN/first-generation DAA/RBV developed anti-IMPDH2 autoantibodies comparable to previous studies including patients under IFN/RBV therapy. Anti-IMPDH2 titers show no use as a marker for therapy outcome in CHC GT1 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF